Bremelanotide (PT-141/Vyleesi): Evidence, Safety, and FDA Status

What Is Bremelanotide?

Bremelanotide is a melanocortin receptor agonist. “PT-141” is the development name still commonly used in research and gray-market advertising. The FDA-approved product, Vyleesi, is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women when the low desire causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance.

The current label specifically says Vyleesi is not indicated for HSDD in postmenopausal women or in men and is not indicated to enhance sexual performance.

Mechanism of Action

• Melanocortin receptor agonism: bremelanotide activates melanocortin receptors, including MC4R, in pathways involved in sexual desire and arousal.
• Central rather than PDE5-style vascular action: its pharmacology differs from sildenafil and other PDE5 inhibitors; that mechanistic difference does not make it an established substitute for erectile-dysfunction therapy.
• Mechanism is not the indication: activity in sexual-arousal pathways does not establish efficacy for every libido, erectile-function, or performance claim used in online marketing.

What the Evidence Shows

• Approved HSDD indication: the two randomized, double-blind, placebo-controlled phase 3 RECONNECT trials enrolled premenopausal women with HSDD and found statistically significant improvements in sexual desire and reductions in distress related to low desire.
• Magnitude and endpoint matter: the registration evidence supports a defined HSDD treatment effect; it should not be translated into a blanket “libido enhancer” or sexual-performance claim.
• Men / erectile dysfunction: earlier studies explored PT-141 in men, but Vyleesi is not FDA-approved for men or for erectile dysfunction. Those exploratory data are a different evidence base from the phase 3 HSDD program.

Evidence quality: strong for the FDA-reviewed indication and substantially weaker for the broader uses commonly attached to “PT-141” marketing.

FDA & Product Status

• Vyleesi: FDA-approved, prescription-only bremelanotide for the specific HSDD indication described above.
• Gray-market “PT-141”: a seller's research-use label does not convert an unapproved product into the FDA-approved drug and does not establish equivalent identity, sterility, concentration accuracy, or manufacturing quality.
• Off-label prescribing: lawful clinician prescribing questions are different from the status of an unapproved product sold directly to consumers. Do not treat the words “off label,” “research use,” and “FDA approved” as interchangeable.

Safety Considerations

• Cardiovascular contraindications: current Vyleesi labeling contraindicates use in people with uncontrolled hypertension or known cardiovascular disease.
• Blood pressure and heart rate: the approved label warns that blood pressure can rise transiently and heart rate can decrease after a dose, generally returning toward baseline within about 12 hours.
• Nausea: nausea was common in the clinical program and is one of the most important tolerability limitations.
• Focal hyperpigmentation: the label warns about focal skin and mucosal pigmentation; resolution was not confirmed in every affected patient after discontinuation.
• Product-quality uncertainty: these label data describe FDA-reviewed Vyleesi. They do not validate the purity, dose accuracy, sterility, or safety of a gray-market vial sold as PT-141.

Bottom Line

Bremelanotide has real phase 3 evidence and an FDA-approved product, but only for a defined HSDD population. The existence of Vyleesi is not evidence that every PT-141 product or marketed use is FDA-reviewed. For this compound, the most important distinction is not “peptide vs. drug”; it is approved product and indication vs. unapproved product or unsupported use.